MYELOMA NEWS
JULY 2016
DARZALEX NOW APPROVED BY HEALTH CANADA
IMPORTANT NEWS!
NEW MYELOMA DRUG APPROVED BY HEALTH CANADA
Myeloma Canada is pleased to share the important news that on June 29th 2016, Health Canada issued a Notice of Compliance with Conditions (NOC/c) approving Janssen Inc.'s new myeloma drug DARZALEX™ (daratumumab) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD. The NOC is conditional on Janssen Inc. providing additional clinical data to Health Canada confirming the clinical benefits of DARZALEX™.
Click here for the link to Janssen Inc. news release
Daratumumab will have to undergo reviews by the pan Canadian Oncology Drug Review (pCODR) and the pan Canadian Pharmaceutical Alliance (pCPA) processes before it can be listed on provincial drug formularies. Myeloma Canada is committed to working diligently with myeloma support groups and patient advocates across the country to ensure this new and innovative treatment is made available to myeloma patients across the country in a timely manner.
Walk the Walk. Make Myeloma Matter.
Click on one of the 12 cities below to sign up or donate to the Multiple Myeloma March
